This November

the gray-market pt-141 purity record is running a 37% failure rate while the forums keep posting

Independent peptide quality testing, most recently updated in late October 2026, has tracked 117 gray-market PT-141 samples from 32 suppliers since early 2025. The failure rate on purity sits around 37% under standard laboratory thresholds. The most recently published supplier ratings, dated October 29, show at least one source with zero passing purity tests across four submitted samples — results running from 94% to 99% against a 99.5% minimum cutoff. A second supplier's October 29 update shows a 69% cumulative pass rate across 18 months of testing. This is not a theoretical concern about an obscure compound. PT-141 — the online alias for the FDA-approved drug bremelanotide — currently circulates on TikTok and in peptide forums for sexual function, appetite, and energy claims. It is frequently described in those spaces as one of the more legitimate peptides, partly because a real FDA-approved version exists. What those spaces do not regularly acknowledge is that the approval belongs to a specific product, used in a specific context, by a specific patient population — and that the gray-market vials being discussed are tested separately, with roughly a third of them failing.

The molecule

bremelanotide activates mc4r — the fda approved it in 2019 for one specific indication in premenopausal women

Bremelanotide is a melanocortin receptor agonist that activates MC4R — the melanocortin-4 receptor — through central nervous system pathways involved in sexual desire signaling. It is not a peripheral vasodilator like sildenafil. The mechanism works through brain signaling rather than local blood-flow changes, which is part of why Palatin Technologies pursued it for hypoactive sexual desire disorder rather than erectile function. The FDA approved bremelanotide in June 2019 as Vyleesi — the first melanocortin agonist approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), a clinical diagnosis requiring that the low desire be distressing and not explained by another condition, medication, or relationship factor. [DailyMed's bremelanotide label](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bremelanotide) records the approved indication, the injection format, and a prominent nausea warning: roughly 40% of Phase 3 participants reported nausea, and 13% stopped the drug because of it. The molecule works in the central nervous system. The side effects reflect that. The online pitches for it usually skip that part.

The gap

pt-141 travels online for male sexual dysfunction and, since 2025, for appetite suppression alongside glp-1s

The internet's PT-141 story runs well outside the approved indication. The oldest claim is male erectile dysfunction — predating the approval and rooted in early Palatin trials that never reached an FDA approval for that use. The more recent addition is appetite suppression, which arrived after [Palatin's Phase 2 press release on BioSpace in April 2025](https://www.biospace.com/press-releases/palatin-reports-positive-appetite-suppression-results-from-phase-2-obesity-study-of-mc4r-agonist-bremelanotide-and-tirzepatide) reported that a Phase 2 study of bremelanotide co-administered with tirzepatide met its primary endpoint. Bremelanotide alone produced a 79% improvement in fullness ratings in the trial, outperforming tirzepatide's 62%. That result traveled through peptide forums and GLP-1 discussion threads as evidence that PT-141 works for weight management. What it doesn't say: the trial was 8 weeks, used low doses, and was not designed to optimize weight loss. The principal investigator quoted in the release said exactly that. The result is an early signal from a Phase 2 study designed to generate a hypothesis for next-generation MC4R agonists. The forum read on it was something bigger. Those are not the same conclusions.

What the data says

the phase 3 trials that earned the approval are real — the evidence for other uses is narrow or absent

The two Phase 3 trials that produced Vyleesi's 2019 approval were randomized, placebo-controlled studies in premenopausal women with clinically diagnosed HSDD. The primary endpoint was patient-reported: a measure of satisfying sexual events and desire, over approximately 24 weeks per trial. Results showed statistically significant improvement in both endpoints versus placebo. [PubMed's bremelanotide literature](https://pubmed.ncbi.nlm.nih.gov/?term=bremelanotide) contains the clinical pharmacology work, the Phase 3 publications, and the nausea-mechanism papers that explain the tolerance tradeoffs. That is a real controlled human evidence record for a specific population and indication. The male ED use case was investigated in Phase 2 but not taken to approval. The obesity/appetite evidence consists of one Phase 2 eight-week study with a low-dose design — not a weight-loss endpoint, not a long-duration trial, and not an approved indication. [ClinicalTrials.gov's bremelanotide registry](https://clinicaltrials.gov/search?term=bremelanotide) documents the full trial footprint, including where the evidence ends. What the evidence does not contain is any trial of gray-market PT-141 vials with the purity profiles that independent quality testing documents. The approval was for a specific pharmaceutical-grade product. The gray market is a separate experiment no one designed.

Approved — PeptideFactCheck stance

the tier holds for the labeled use — the gray market is a different risk category with a different purity record

Bremelanotide holds PeptideFactCheck's Approved evidence tier. That classification reflects what the tier means: regulatory certainty for labeled uses, not a blank check for every claim that shares the molecule's name. The 2019 FDA approval covers premenopausal women with acquired, generalized HSDD. The nausea signal is documented and reproduced in both Phase 3 trials. The cardiovascular caution that led to the original nasal-spray formulation's clinical hold in 2007 informed the final subcutaneous-injection design. The Approved tier's tone says the molecule has a label. What the Approved tier cannot do is follow the molecule into gray-market products sold as PT-141, where independent quality testing documents failure rates around 37% of tested samples, where the indications discussed online extend far beyond the approved indication, and where the Phase 2 obesity data is being read as an approved use rather than a preliminary investigational signal. [The FDA Orange Book](https://www.accessdata.fda.gov/scripts/cder/ob/) lists Vyleesi by name. It doesn't list the gray-market vials. That difference is the receipt. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.